The approach uses activity-based nanosensor technology being commercialized by spin-out Glympse Bio to detect dysregulated protease activity linked to disease.
The approach, called Lung-CLiP, couples machine learning trained on epigenetic and clonal frequency data with the detection of alterations in blood-borne DNA.
Two recent acquisitions have resulted in the swift launch of two assays, one for the clinic and another for research use, as the firm's original test finally nears validation.
The company reported a net loss of $8.0 million, or $.15 per share, as it saw increased costs associated with its transition to commercial test provision.
An analysis of lung adenocarcinoma brain metastases uncovered more frequent amplifications or deletions in a handful of genomic regions, pointing to potential drivers.
Through a startup called FCS Technology, the team is hoping to market the platform for cancer research and, eventually, clinical diagnostic applications.
A retrospective cohort study uncovered microRNA signatures that could tell lung cancer patients apart from others, including patients with other, non-tumor lung conditions.
The firm posted $29.7 million in revenues, up about 15 percent from $25.8 million in Q4 2018 and slightly above the analysts' average estimate of $29.5 million.
The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.
In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.
